Calliditas Therapeutics AB — key financial figures for fiscal year 2023 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2023)

kr 1.2B

Net Income/Loss (FY2023)

-kr 466.2M

Total Assets (FY2023)

kr 1.9B

Total Equity (FY2023)

$334.8M

Cash Flows from Operating Activities (FY2023)

-kr 434.7M

Source: Calliditas Therapeutics AB 20-F filing (FY2023). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.